The utility of IMP3 immunohistochemical staining in differentiating nodular lymphocyte predominant Hodgkin Lymphoma from T-Cell/Histiocyte-Rich large B-Cell lymphoma.
Nodular lymphocyte predominant Hodgkin lymphoma, T cell/histiocyte-rich large B-cell lymphoma, IMP3, Immunohistochemistry
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
28 Dec 2022
28 Dec 2022
Historique:
received:
19
08
2022
accepted:
15
11
2022
entrez:
28
12
2022
pubmed:
29
12
2022
medline:
31
12
2022
Statut:
epublish
Résumé
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) and T cell/histiocyte-rich large B-cell lymphoma (THRLBCL) have overlapping histological features that make their diagnosis challenging. Insulin-like growth factor II mRNA-binding protein 3 (IMP3) is a recently proposed diagnostic marker for Hodgkin's lymphoma. The aim of this study was to determine the ability of IMP3 in differentiating NLPHL from THRLBCL. In this retrospective study, the formalin-fixed paraffin-embedded blocks from 56 patients (28 NLPHL and 28 large B cell lymphoma (LBCL, including 16 THRLBCL and 12 DLBCL, NOS) cases based on immunohistochemistry (IHC) were included. Sample sections were stained for IMP3 using IHC method. Moderate to strong staining in at least 10% of tumor cells was considered positive IMP3 expression. The mean age of the patients was 41.25 ± 16.08 years old. The majority of the patients were male. There was a significant age difference between NLPHL (34.61 ± 16.44 years old) and LBCL (47.89 ± 12.85 years) groups (p = 0.001). No significant difference was seen in gender and site between NLPHL and LBCL groups. The expression of IMP3 was mainly strong in LBCL group, while it was heterogeneously distributed among NLPHL samples ranging from weak to strong (p < 0.001). It was determined that strong IMP3 expression at 55.00% can differentiate LBCL from NLPHL with 71.4% sensitivity and 71.4% specificity. Our findings showed that IMP3 may be a good complement in differentiating NLPHL cases from THRLBCL.
Identifiants
pubmed: 36577979
doi: 10.1186/s12885-022-10321-z
pii: 10.1186/s12885-022-10321-z
pmc: PMC9795661
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1359Subventions
Organisme : Tehran University of Medical Sciences and Health Services
ID : 51184
Informations de copyright
© 2022. The Author(s).
Références
Hum Pathol. 2010 Dec;41(12):1726-34
pubmed: 20825974
Ann Surg Oncol. 2009 Dec;16(12):3499-506
pubmed: 19672661
Hum Pathol. 2013 Oct;44(10):2167-72
pubmed: 23845468
BMC Cancer. 2010 Jun 30;10:341
pubmed: 20591150
PLoS One. 2013 Nov 11;8(11):e78812
pubmed: 24244368
Mech Dev. 1999 Oct;88(1):95-9
pubmed: 10525192
Hum Pathol. 2009 Dec;40(12):1699-705
pubmed: 19698973
Hum Pathol. 2009 Nov;40(11):1528-33
pubmed: 19695680
Blood Cancer J. 2021 Dec 18;11(12):203
pubmed: 34923571
Appl Immunohistochem Mol Morphol. 2011 Oct;19(5):413-6
pubmed: 21436679
Am J Surg Pathol. 2011 Jun;35(6):878-82
pubmed: 21566519
Am J Surg Pathol. 2009 Apr;33(4):521-5
pubmed: 19047899
Adv Anat Pathol. 2014 May;21(3):191-200
pubmed: 24713990
Mod Pathol. 2013 Jan;26 Suppl 1:S57-70
pubmed: 23281436
Am J Pathol. 2002 Nov;161(5):1861-7
pubmed: 12414532
Blood. 2003 Nov 15;102(10):3753-8
pubmed: 12881319
J Craniofac Surg. 2011 Nov;22(6):2022-5
pubmed: 22067851
Mol Cell Biol. 1999 Feb;19(2):1262-70
pubmed: 9891060
Oncogene. 1997 Jun 5;14(22):2729-33
pubmed: 9178771
Case Rep Pathol. 2014;2014:956217
pubmed: 25110597
Am J Surg Pathol. 2008 Aug;32(8):1252-7
pubmed: 18594468
J Hematop. 2009 Dec 22;2(4):211-36
pubmed: 20309430
Histopathology. 2012 Jan;60(2):278-86
pubmed: 22211286
Blood. 2020 Dec 24;136(26):2987-2993
pubmed: 32877522
Am J Surg Pathol. 2003 Oct;27(10):1346-56
pubmed: 14508396
J Exp Med. 2008 Sep 29;205(10):2251-68
pubmed: 18794340